期刊文献+

血液病患者巨细胞病毒和EB病毒定量检测的临床价值 被引量:4

原文传递
导出
摘要 目的 评价实时荧光定量聚合酶链反应(PCR)对血液系统疾病患者巨细胞病毒(CMV)和EB病毒(EBV)感染的早期诊断价值.方法 应用实时荧光定量PCR检测271例血液系统疾病患者和28名健康对照者血液中CMV DNA和EBV DNA的含量.结果 28名健康对照者CMV DNA和EBVDNA均阴性.271例患者中147例检测EBV,阳性率为24.5%(36/147);124例检测CMV,阳性率为4.8%(6/124),DNA介于102~ 106基因拷贝/ml,治疗有效者EBV DNA和CMVDNA均迅速下降,1~3周后转阴.结论 实时荧光定量PCR动态监测血液系统疾病患者CMV DNA和EBV DNA水平对CMV和EBV感染的早期诊断和疗效判断具有重要意义.
出处 《白血病.淋巴瘤》 CAS 2014年第8期497-499,共3页 Journal of Leukemia & Lymphoma
基金 黑龙江省自然科学基金(QC2010052)
  • 相关文献

参考文献6

  • 1Torres HA,Aguilera E,Safdar A,et al.Fatal cytomegalovirus pneumonia in patients with haematological malignancies:an autopsybased case-control study[J].Clin Microbiol Infect,2008,14:1160-1166.
  • 2Lee AD,Gama-Rodrigues J,Galv(a)o FH,et al.Study of morbidity in orthotopic small intestine transplantation with Wistar rats.Experimental study[J].Arq Gastroenterol,2002,39:39-47.
  • 3冯术青,朱梦波,闫兴双,崔晓聪,李晓宇,杜小梅,高峰.实时定量聚合酶链反应在异基因造血干细胞移植后巨细胞病毒感染的诊断和治疗中的应用[J].白血病.淋巴瘤,2012,21(2):120-121. 被引量:2
  • 4Snow AL,Lambert SL,Natkunam Y,et al.EBV can protect latently infected B cell lymphomas from death receptor-induced apoptosis[J].J Immunol,2006,177:3283-3293.
  • 5张丽,竺晓凡,吴克复.EBV与血液系统恶性肿瘤相关性的研究进展[J].白血病.淋巴瘤,2005,14(2):116-118. 被引量:6
  • 6Ishii M,Yamaguchi N,Ohshima S,et al.Possibility of preventive treatment for EBV-associated NK cell-lineage proliferative disorders[J].Intern Med,2003,42:250-254.

二级参考文献34

  • 1N L Harris,E S Jaffe,J Diebold,G Flandrin,H K Muller-Hermelink,J Vardiman,T A Lister,C D Bloomfield,张凤奎,郝玉书.世界卫生组织(WHO)造血与淋巴组织肿瘤分类方案:临床顾问委员会会议报告[J].白血病.淋巴瘤,2001,10(3):171-181. 被引量:20
  • 2贾晋松,刘东平,黄晓军,吴彤,刘代红,张耀臣,苏宏,王静波,周葭蕤,刘强,殷宇明,孙瑞娟,段萱,陆道培.异基因造血干细胞移植后人类巨细胞病毒pp65的监测及疗效、危险因素分析[J].中国实验血液学杂志,2006,14(4):749-754. 被引量:10
  • 3张王刚,陈银侠,曹星梅,王香玲,王俊宏,刘捷,王剑利,李陕区.多发性骨髓瘤患者EB病毒DNA的检测[J].中华血液学杂志,1996,17(11):595-596. 被引量:12
  • 4Stephen AL, Thomp son CH, TattersaU MH, et al. Analysis of mutations in the URR and E6 /E7 oncogenes of HPV 16 cervical cancer isolates from central China. Int J Cancer, 2000, 86: 695-701.
  • 5Lu DP, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow translpantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood, 2006, 107: 3065- 3073.
  • 6Gerna G, Lilleri D, Baldanti F, et al. Human cytomegalovirus immediate early mRNAemia versus pp65 antigenemia for guiding preemptive therapy in children and young adults undergoing hematopoietie stem cell transplantation: a prospective, randomized, open-label trial. Blood, 2003, 101: 5053-5060.
  • 7Boeckh M, Nichols WG, Papanioolaou G, et al. Cytomegalovirus in hematopoietie stem cell transplant recipients:Current status, known challenges,and future strategies. Biol Blood Marrow Transplant, 2003, 9: 543-558.
  • 8Maecker HT, Maino VC. Analyzing T-cell responses to cytomegalovirus by cytokine flow cytometry. Hum Immunol, 2004, 65: 493-499.
  • 9Reusser P, Einsele H, Lee J, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood, 2002, 99: 1159-1164.
  • 10Daly A, McAfee S, Dey B, et al. Nonmyeloablative bone marrow transplantation: Infectious complications in 65 recipients of HLA- identical and mismatched transplants. Biol Blood Marrow Transplant, 2003, 9: 373-382.

共引文献6

同被引文献37

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部